These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 30800562)

  • 41. Real-world evidence for long-term safety and effectiveness of ipragliflozin in treatment-naïve versus non-naïve Japanese patients with type 2 diabetes mellitus: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM).
    Maegawa H; Tobe K; Nakamura I; Uno S
    Diabetol Int; 2021 Oct; 12(4):430-444. PubMed ID: 34567926
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen.
    Onishi Y; Ishii H; Oura T; Takeuchi M
    Diabetes Ther; 2020 Mar; 11(3):735-745. PubMed ID: 31994009
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study.
    Kang SM; Yun HM; Sohn M; Lim S
    Diabetes Obes Metab; 2023 Jul; 25(7):1922-1931. PubMed ID: 36932823
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of monotherapy with enavogliflozin in Korean patients with type 2 diabetes mellitus: Results of a 12-week, multicentre, randomized, double-blind, placebo-controlled, phase 2 trial.
    Yang YS; Min KW; Park SO; Kim KS; Yu JM; Hong EG; Cho SR; Won KC; Kim YH; Oh S; Choi SH; Koh G; Huh W; Kim SY; Park KS
    Diabetes Obes Metab; 2023 Aug; 25(8):2096-2104. PubMed ID: 37016484
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes receiving conventional therapy: clinical implication of the importance of exercise habits during treatment with ipragliflozin.
    Kato M; Sakai K; Saito K; Tsutsui K; Yamashita S; Kato N
    Diabetol Int; 2017 Aug; 8(3):275-285. PubMed ID: 30603333
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differing Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Ipragliflozin on the Decrease of Fat Mass vs. Lean Mass in Patients With or Without Metformin Therapy.
    Nagai Y; Fukuda H; Kawanabe S; Nakagawa T; Ohta A; Tanaka Y
    J Clin Med Res; 2019 Apr; 11(4):297-300. PubMed ID: 30937121
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparing the efficacy of apple peels and a sodium-glucose cotransporter 2 inhibitor (ipragliflozin) on interstitial glucose levels: A pilot case study.
    Okada J; Yamada E; Okada K; Okada S; Yamada M
    Curr Ther Res Clin Exp; 2020; 93():100597. PubMed ID: 32874375
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical response to sodium glucose co-transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma.
    Izumi K; Iimura Y; Hiruma K; Touma T; Tsukamoto T
    IJU Case Rep; 2019 Sep; 2(5):269-271. PubMed ID: 32743434
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations.
    Deerochanawong C; Chan SP; Matawaran BJ; Sheu WH; Chan J; Man NH; Suastika K; Khoo CM; Yoon KH; Luk A; Mithal A; Linong J
    Diabetes Obes Metab; 2019 Nov; 21(11):2354-2367. PubMed ID: 31264765
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.
    Frias JP; Gonzalez-Galvez G; Johnsson E; Maaske J; Testa MA; Simonson DC; Dronamraju N; Garcia-Sanchez R; Peters AL
    Diabetes Obes Metab; 2020 Jul; 22(7):1083-1093. PubMed ID: 32052516
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Real-world risk of hypoglycemia-related hospitalization in Japanese patients with type 2 diabetes using SGLT2 inhibitors: a nationwide cohort study.
    Horii T; Oikawa Y; Kunisada N; Shimada A; Atsuda K
    BMJ Open Diabetes Res Care; 2020 Nov; 8(2):. PubMed ID: 33246930
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials.
    Kashiwagi A; Shestakova MV; Ito Y; Noguchi M; Wilpshaar W; Yoshida S; Wilding JPH
    Diabetes Ther; 2019 Dec; 10(6):2201-2217. PubMed ID: 31606880
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy.
    Ishihara H; Yamaguchi S; Sugitani T; Kosakai Y
    Clin Drug Investig; 2019 Dec; 39(12):1213-1221. PubMed ID: 31552641
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination Therapy with Empagliflozin and Insulin Results in Successful Glycemic Control: A Case Report of Uncontrolled Diabetes Caused by Autoimmune Pancreatitis and Subsequent Steroid Treatment.
    Kishimoto M; Yamaoki K; Adachi M
    Case Rep Endocrinol; 2019; 2019():9415347. PubMed ID: 30895163
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study.
    Ishihara H; Yamaguchi S; Nakao I; Okitsu A; Asahina S
    Diabetes Obes Metab; 2016 Dec; 18(12):1207-1216. PubMed ID: 27436788
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term (52-week) efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open-label extension of a phase III study.
    Kaku K; Isaka H; Sakatani T; Toyoshima J
    J Diabetes Investig; 2020 May; 11(3):662-671. PubMed ID: 31743569
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study.
    Ishihara H; Yamaguchi S; Nakao I; Sakatani T
    Diabetes Ther; 2018 Aug; 9(4):1549-1567. PubMed ID: 29926400
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double-blind, phase 3 trial.
    Kaku K; Isaka H; Sakatani T; Toyoshima J
    Diabetes Obes Metab; 2019 Oct; 21(10):2284-2293. PubMed ID: 31173455
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study.
    Ishihara H; Yamaguchi S; Nakao I; Asahina S; Sakatani T
    Diabetol Int; 2019 Jan; 10(1):37-50. PubMed ID: 30800562
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.